BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category

The use of radioiodine therapy (RIT) is debated in intermediate-risk differentiated thyroid cancer (DTC) patients. The understanding of the molecular mechanisms involved in the pathogenesis of DTC can be useful to refine patient selection for RIT. We analyzed the mutational status of BRAF, RAS, TERT...

Descripción completa

Detalles Bibliográficos
Autores principales: Pizzimenti, Cristina, Fiorentino, Vincenzo, Ieni, Antonio, Rossi, Esther Diana, Germanà, Emanuela, Giovanella, Luca, Lentini, Maria, Alessi, Ylenia, Tuccari, Giovanni, Campennì, Alfredo, Martini, Maurizio, Fadda, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298643/
https://www.ncbi.nlm.nih.gov/pubmed/37373171
http://dx.doi.org/10.3390/ijms241210024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298643/
https://www.ncbi.nlm.nih.gov/pubmed/37373171
http://dx.doi.org/10.3390/ijms241210024

Ejemplares similares